Allergic Rhinitis/Seasonal Allergies

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)
   Allergic rhinitis is a classic Type I (immediate) hypersensitivity reaction driven by an immunoglobulin E (IgE)-mediated inflammatory response within the nasal mucosa [442, 589]. The cellular mechanism unfolds in three distinct phases:

Sensitization Phase: Initial exposure of a genetically predisposed host to airborne antigens (pollen, dust mites, mold, animal dander) triggers T helper 2 (Th2) cells to drive the synthesis of antigen-specific IgE by plasma cells [442, 250]. These IgE antibodies immediately bind to high-affinity receptors (FcεRI) on the membranes of mast cells and basophils [586, 772].
Early-Phase (De-granulation) Response: Upon re-exposure, the multivalent allergen cross-links adjacent IgE molecules on the sensitized mast cells, triggering a rapid intracellular signaling cascade that induces de-granulation of preformed mediators (primarily histamine) [250, 586].
Late-Phase (Infiltration) Response: Over hours, lipid-derived mediators (leukotrienes, prostaglandins, platelet-activating factor) and Th2-derived cytokines are synthesized and released [442, 608]. This recruits an intense multicellular inflammatory infiltrate—predominated by eosinophils, lymphocytes, and neutrophils—into the submucosa, amplifying local edema, mucosal hyper-reactivity, and vascular engorgement [109, 443, 586].

The Ultimate Bedside Mechanism

Histamine binding to H1 receptors on nasal sensory neurons directly stimulates nasal pruritus, paroxysmal sneezing, and reflex parasympathetic activity (rhinorrhea) [250, 443].
Simultaneous H1 receptor activation on local endothelial cells promotes profound vasodilation and increased microvascular permeability, producing turbinate engorgement and nasal obstruction [250, 443, 608].
2. THE BEDSIDE ACTION PLAN (Rapid ER Management)
While uncomplicated allergic rhinitis does not cause primary respiratory failure, 80% of pediatric asthmatics have co-existing allergic rhinitis, and untreated nasal inflammation directly destabilizes lower airway mechanics [248].

Step 1: Immediate Triage & Comorbidity Screen
Assess ABCs and respiratory effort. Allergic rhinitis alone never causes airway compromise, stridor, or hemodynamic instability [421, 422]. If these are present, immediately pivot to the Anaphylaxis Treatment Protocol (IM Epinephrine 0.3–0.5 mg [1:1000] in anterolateral thigh) [619, 796] or Acute Asthma/Status Asthmaticus Protocol [134].
Perform immediate chest auscultation to screen for silent or active bronchospasm/wheezing [425].
Step 2: First-Line Pharmacotherapy (Standard of Care)
Intranasal Corticosteroids (Universal First-Line Gold Standard) [423, 448]:
Fluticasone furoate (27.5 μg/spray): Administer 2 sprays in each nostril daily (adults/children ≥12 years) [428]; 1 spray in each nostril daily (children 2–11 years) [433].
Fluticasone propionate (50 μg/spray): Administer 1–2 sprays in each nostril daily (adults/children ≥12 years) [428]; 1 spray in each nostril daily (children 4–11 years) [434].
Mometasone furoate (50 μg/spray): Administer 2 sprays in each nostril daily (adults/children ≥12 years) [428]; 1 spray in each nostril daily (children 2–11 years) [433].

Nonsedating (Second-Generation) Oral H1 Antihistamines [428, 447]

Cetirizine: 5–10 mg PO once daily (adults) [429]; 5 mg PO daily in geriatric patients >65 years to minimize anticholinergic side effects [429]; 2.5 mg PO daily (pediatric age 2–5) [435]; 5 mg PO daily (pediatric age 6–11) [435].
Loratadine: 10 mg PO once daily (adults/pediatric >6 years) [430, 435]; 5 mg PO daily (pediatric age 2–5) [435].
Fexofenadine: 60 mg PO twice daily or 180 mg PO once daily [203, 208]; 30 mg PO twice daily (pediatric age 2–11) [203, 435].
Intranasal Antihistamines (Superior to oral for local nasal symptoms) [448]:
Azelastine 0.1% or 0.15%: 1–2 sprays in each nostril every 12 hours [429].
Olopatadine (665 μg/spray): 2 sprays in each nostril every 12 hours [430].
Leukotriene-Receptor Antagonists (Highly safe; approved down to age 6 months) [448]:
Montelukast: 10 mg PO once daily (adults) [430]; 4 mg PO daily (children age 2–5) [435]; 5 mg PO daily (children age 6–11) [436].

Adjunctive Therapies

Intranasal Saline Irrigation/Spray: Reduces mucosal allergen load and medication burden [252, 428].
Intranasal Ipratropium Bromide (0.03%–0.06%): 2 sprays per nostril every 8–12 hours [432]. Indicated exclusively for refractory, profuse watery rhinorrhea (warn patient of potential nasal dryness) [432, 450].
Step 3: Severe Refractory Flares
Systemic Corticosteroids (Short Course): Prescribe Prednisone 1 mg/kg PO daily for 5 days (maximum daily dose 60 mg) [432] or Prednisolone 1 mg/kg PO daily for 5 days (maximum 60 mg) [432]. Use selectively for extreme symptoms failing standard multi-agent regimens [449].
3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)
Board examiners frequently place a patient with rhinorrhea in a clinical vignette to test your ability to separate benign allergic processes from critical or structural airway conditions.

Diagnosis Key Clinical Discriminators Diagnostic Workup Strategy
Vasomotor Rhinitis (Non-inflammatory) [426] Nasal congestion and clear rhinorrhea triggered by physical stimuli (cold dry air, temperature shifts, eating) [426, 423]; characteristically lacks nasal ocular pruritus, sneezing, or systemic atopy [423, 524]. • Purely clinical diagnosis.• Confirm via lack of response to antihistamines and complete absence of allergen-specific IgE on skin/serum testing [426, 445].
Infectious Rhinitis (Common Cold / URI) [427] Acute onset (<7–10 days) predominated by throat irritation/sore throat, malaise, fever (common in children) [95], and progressive conversion of nasal discharge from clear to thick, purulent, or discolored [194, 298]. • Clinical evaluation; no routine labs or imaging in uncomplicated cases [95, 195].• Throat swab, rapid strep test, or viral PCR panel if pharyngitis or influenza co-exists [364, 878].
Cerebrospinal Fluid (CSF) Rhinorrhea [427] Strictly unilateral, clear, watery nasal discharge that characteristically drips profusely when leaning forward or performing a Valsalva maneuver [427, 349]; often associated with a prior head injury, facial trauma, or sinus surgery [349]. • Emergency skull/facial CT to identify cribriform plate or ethmoid roof defect [186].• Analyze fluid for Beta-2 transferrin (gold standard) or check bedside "halo" filter paper test if blood-tinged [554].
Nasal Foreign Body [427, 378] Presenting triad of strictly unilateral, persistent, purulent, and extremely foul-smelling (bromhidrosis) nasal discharge [254, 376], typically in a toddler, pediatric patient, or disabled adult [191, 378]. • Direct visual inspection utilizing a nasal speculum and headlamp [379].• Plain radiography only if metallic, button battery, or magnetic jewelry is suspected [382, 788].
Granulomatosis with Polyangiitis (GPA) [576] Systemic necrotizing vasculitis presenting with chronic sinus pain, significant nasal crusting (characteristically absent in allergic rhinitis) [576], recurrent epistaxis, saddle nose deformity (cartilage destruction) [554, 576], and hematuria. • Urinalysis (screen for glomerulonephritis).• Serum c-ANCA (PR3-ANCA) antibodies.• Non-contrast temporal bone/sinus CT demonstrating bony erosion or septal perforation [347, 576].

Prioritized ED Workup Strategy

Uncomplicated allergic rhinitis is a clinical diagnosis; routine blood panels (CBC, BMP, inflammatory markers) and imaging are not indicated [419, 425].
Gold Standard Testing (Outpatient only): Epicutaneous skin prick testing is the preferred modality to guide immunotherapy [445]. Alternative: Serum allergen-specific IgE testing (similar sensitivity/specificity) [445]. Total IgE is neither sensitive nor specific [252].
4. THE VISUAL BOARD (ECG / POCUS / Imaging)
While allergic rhinitis is an inflammatory mucosal disease, examiners will test your knowledge of visual diagnostics to rule out mimics and assess medication toxicity.

ECG Checklist

Uncomplicated allergic rhinitis has no primary ECG findings.
Drug Toxicity Screen: In patients taking high-dose oral decongestants (e.g., pseudoephedrine), look for sinus tachycardia, premature ventricular contractions (PVCs), or atrial tachyarrhythmias (due to systemic alpha- and beta-adrenergic stimulation) [450].
In patients taking tricyclic-like sedating antihistamines (e.g., doxepin, diphenhydramine) [214], look for QTc prolongation or signs of sodium-channel blockade (widened QRS, terminal R wave in aVR) [550, 723].

POCUS / Bedside Ultrasound Checklist

Maxillary and Frontal Sinuses: Can be utilized to screen for fluid levels, mucosal thickening, or sinus opacification to rule out complicating acute bacterial rhinosinusitis [194, 806].
Airway (Rule out Epiglottitis / Laryngeal Edema mimic): Transverse neck ultrasound demonstrating an anteroposterior (AP) epiglottis diameter >3.6 mm [393] or the classic sagittal "Alphabet P sign" (created by the shadow of the hyoid bone and the edematous, hypoechoic epiglottis) [393].

Computed Tomography (CT) / Plain X-ray

Not indicated for allergic rhinitis. If performed incidentally, it may show symmetric mucosal thickening of the nasal passages and engorgement of the inferior turbinates without sinus opacification or air-fluid levels [888].
Caution: Sinus mucosal thickening persists on CT for up to 8 weeks following a resolved bout of sinusitis [326]; do not misinterpret this as active bacterial disease [327].
5. THE SCORING MATRIX (Risk Stratification & Guidelines)
Allergic rhinitis does not utilize a primary ED risk-scoring tool; however, the board examiner expects the resident to utilize the following validated guidelines for proper triage and disposition:

1. The PODS Criteria (Acute Rhinosinusitis Diagnostic Guideline) [300]
   Utilized to differentiate allergic rhinitis from complicating rhinosinusitis. Diagnosis is established if at least 2 of the following 4 features are present, one of which must be Nasal Obstruction or Purulent/Discolored Nasal Discharge [300]:

P - Pain (Facial pain, pressure, or fullness) [300]
O - Obstruction (Nasal obstruction/blockage) [300]
D - Discharge (Purulent/discolored nasal or postnasal discharge) [300]
S - Smell disorder (Hyposmia/anosmia) [300]
Disposition Impact: Allergic rhinitis exhibits clear rhinorrhea [425]; the presence of purulent (colored) drainage and a duration of ≥10 days without improvement (or the "double sickening" phenomenon) shifts the diagnosis to Acute Bacterial Rhinosinusitis, requiring different treatment [304, 888].
2. ARIA (Allergic Rhinitis and its Impact on Asthma) Guidelines [451]
Mild: No sleep disturbance, no limitation of daily activities/sports, normal school/work performance, and no troublesome symptoms [251, 441].
Moderate-to-Severe: Presence of at least one of: sleep disturbance, impairment of daily activities, poor school/work performance, or highly troublesome symptoms [251, 441].
Disposition Impact: Moderate-to-severe disease warrants the immediate initiation of intranasal corticosteroids as first-line therapy (rather than PRN antihistamines) [423, 448].
6. THE DANGER ZONE (Pitfalls & Critical Actions)
Avoid these critical examiner-mandated traps to prevent catastrophic diagnostic closures and medication mishaps:

Pitfall 1: Missing the Asthma Connection (The Pediatric Traps)
The Danger: Failing to realize that 80% of children with asthma have allergic rhinitis [248]. Failing to auscultate the lungs in a child presenting with "seasonal congestion and chronic night cough" can lead to missing a silent, severe asthma exacerbation [425, 737].
Critical Action: Always perform a complete, bilateral lung exam and check pulse oximetry on all patients presenting with allergic rhinitis [425, 738].
Pitfall 2: Inducing Rhinitis Medicamentosa (Rebound Edema)
The Danger: Failing to counsel patients on the strict limits of topical nasal decongestants (e.g., oxymetazoline, phenylephrine, naphazoline) [450]. Overuse causes severe down-regulation of alpha-receptors, leading to rebound mucosal edema and intractable congestion [450, 197].
Critical Action: Limit topical nasal decongestant use to a maximum of 3 consecutive days [450, 197].
Pitfall 3: Systemic Decongestant Toxicity in High-Risk Patients
The Danger: Prescribing or recommending oral pseudoephedrine/phenylephrine to patients with uncontrolled hypertension, coronary artery disease, cardiac dysrhythmias, cerebrovascular disease, closed-angle glaucoma, or hyperthyroidism [450, 451]. The systemic alpha-adrenergic effects can precipitate acute hypertensive crises, strokes, or fatal dysrhythmias [450, 451].
Critical Action: Screen all patients for cardiovascular disease before recommending oral decongestants, and do not routinely use them in pediatric patients [431, 436].
Pitfall 4: Prescribing Contraindicated Medications in Pregnancy
The Danger: Prescribing oral decongestants (associated with vascular/teratogenic risks in the first trimester) or oral/systemic corticosteroids to a pregnant patient [453, 454].
Critical Action: Maintain first-line safety in pregnancy by utilizing only intranasal corticosteroids, H1 oral antihistamines (e.g., cetirizine, loratadine), or sodium cromolyn, which are proven safe [433, 453].
Pitfall 5: Intramuscular Corticosteroid Administration
The Danger: Administering intramuscular corticosteroid depot injections to treat seasonal allergies [449]. This is a severe board-examiner "red flag" due to the risk of local tissue/fat atrophy and systemic side effects [449].
Critical Action: Never administer or prescribe intramuscular corticosteroids for allergic rhinitis [449].
7. MCQ MASTERCLASS (Written Exam Tips)
Multiple-choice questions on allergic rhinitis are high-yield and rely heavily on specific clinical visual signs and biochemical receptor physiology.

Written Board "Buzzwords" & High-Yield Facts

"Allergic salute": A distinct horizontal crease across the lower third of the nasal bridge, caused by chronic, repetitive upward wiping of the nose with the palm of the hand to relieve pruritus [251, 425].
"Dennie-Morgan folds": Symmetric folds or lines beneath the lower eyelids caused by chronic venous congestion and spasm of the local orbicularis oculi muscle, classically associated with atopy [251].
"Allergic shiners": Dark, bluish circles under the eyes caused by chronic venous engorgement of the suborbital subcutaneous tissues due to continuous nasal mucosal obstruction [251].
"Boggy, pale-bluish nasal turbinates": Classically describes the physical appearance of the edematous nasal mucosa in allergic rhinitis [251, 425]. (Differentiate from the bright red, inflamed, or crusting mucosa of viral rhinitis or GPA) [95, 576].
Th2 (T helper 2) cells & Cytokines: The primary immune cells driving IgE production via cytokines such as IL-4, IL-5, and IL-13 [664, 830].

Written Exam Distractors & How to Eliminate Them

The "Vasomotor Rhinitis" Distractor: Look for a patient with rhinorrhea triggered exclusively by cold air, warm food, or positional changes [426]. Eliminate Allergic Rhinitis if the vignette explicitly states "absence of sneezing, nasal pruritus, and negative skin-prick/serum IgE testing" [423, 524].
The "Rhinitis Medicamentosa" Distractor: Look for a patient with "rebound congestion worse than their baseline" [450]. Check the medication list for oxymetazoline or phenylephrine nasal spray use for >3 days [450].
The "GPA (Wegener's)" Distractor: Look for a patient with persistent "sinusitis" symptoms, but with unilateral nasal crusting, septal perforation, or hemoptysis [576]. Allergic rhinitis never causes mucosal ulceration or bony septal destruction [576].
8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)
During an oral board simulation or OSCE, you must demonstrate clinical safety, clear patient communication, and a highly structured, systemic evaluation.

Examiner Communication Pearls
Demonstrate Public Health & Economic Awareness: "allergic rhinitis is one of the most common chronic diseases, affecting up to 60 million people in the U.S. alone [438]. While not acutely life-threatening, it carries a massive economic burden—exceeding $17.5 billion in direct healthcare costs annually [441]—and has a severe impact on patient quality of life due to sleep disturbances, absenteeism, and decreased productivity, known as presenteeism [441]."
Detail Allergen Avoidance: "I will advise the patient to implement strict environmental control measures, including the avoidance of known triggers such as pollen, dust mites, indoor molds, and animal dander [446]."
Mandatory Physical Exam Maneuvers
Airway and HEENT Assessment: "I will inspect the posterior oropharynx to rule out pharyngeal postnasal drip, cobbling, or tonsillar hypertrophy [425, 727]. I will inspect the nasal passages utilizing a nasal speculum oriented in a vertical direction to prevent septal injury and optimize turbinate visualization [818]."
Cardiopulmonary Screen: "I will perform a meticulous chest and lung exam to screen for wheezing or accessory muscle use, as untreated allergic rhinitis is a major trigger for comorbid asthma [425, 737]."
Examiner-Approved Oral Presentation Phrasing
Presenting the Case: "The patient is a 30-year-old female presenting with seasonal nasal congestion, clear rhinorrhea, and paroxysmal sneezing worst in the spring and early autumn [423, 424]. On physical exam, she has boggy, pale-bluish nasal turbinates, clear rhinorrhea, and a visible horizontal nasal crease [425]. Her lung fields are completely clear to bilateral auscultation with no wheezing, and there are no signs of systemic anaphylaxis or airway compromise [421, 425]."

Articulating the Management Plan: "I will initiate standard first-line therapy utilizing intranasal corticosteroids, specifically Fluticasone propionate nasal spray, 1 to 2 sprays in each nostril daily [428]. I will supplement this with a nonsedating second-generation oral H1 antihistamine, such as Cetirizine 10 mg PO once daily, which is preferred over sedating first-generation agents to prevent performance impairment [428, 429, 447]. I will strictly counsel the patient against the use of over-the-counter topical nasal decongestants for more than 3 consecutive days to prevent the development of rhinitis medicamentosa [450, 197]. Lastly, I will discharge the patient home with outpatient referral to a primary care physician or an allergist-immunologist for allergen skin-prick testing and long-term symptom monitoring [438, 445]."